• Publications
  • Influence
Randomized, double-blind, placebo-controlled phase II study of AMG 386 combined with weekly paclitaxel in patients with recurrent ovarian cancer.
PURPOSE To estimate the efficacy and toxicity of AMG 386, an investigational peptide-Fc fusion protein that neutralizes the interaction between the Tie2 receptor and angiopoietin-1/2, plus weeklyExpand
  • 203
  • 5
Sex differences of carotid intima-media thickness in healthy children and adolescents.
OBJECTIVES In pediatric cardiovascular health prevention non-invasive diagnostics of subclinical atherosclerosis is essential for screenings and interventional purposes. Increased carotid arteryExpand
  • 70
  • 5
Randomized phase III study of erlotinib versus observation in patients with no evidence of disease progression after first-line platin-based chemotherapy for ovarian carcinoma: a European
PURPOSE This trial evaluated the efficacy of maintenance erlotinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, after first-line chemotherapy. PATIENTS AND METHODSExpand
  • 71
  • 5
From Pedagogy to Technagogy in Social Work Education: A Constructivist Approach to Instructional Design in an Online, Competency-Based Child Welfare Practice Course
This article documents the design and pilot delivery of a computer-mediated, competency-based child welfare practice course founded on constructivist instructional principles. It was created in 2003Expand
  • 30
  • 2
Single-agent irinotecan or FOLFIRI as second-line chemotherapy for advanced colorectal cancer; results of a randomised phase II study (DaVINCI) and meta-analysis [corrected].
BACKGROUND Second-line treatment with irinotecan for advanced or metastatic colorectal cancer prolongs survival. It is uncertain whether irinotecan is better administered with 5-fluorouracil or aloneExpand
  • 17
  • 1
  • PDF
Randomized phase III study of erlotinib versus observation in patients with no evidence of disease progression after first-line platin-based chemotherapy for ovarian carcinoma: A GCIG and EORTC-GCG
LBA5000 Background: The epidermal growth factor receptor (EGFR) has been found to be overexpressed in 55-98% of advanced epithelial ovarian cancer. This trial evaluated the efficacy of maintenanceExpand
  • 25
  • 1
A randomized, double-blind, placebo-controlled phase II study of the efficacy and safety of farletuzumab (MORAb-003) in combination with weekly paclitaxel in subjects with platinum-resistant or
TPS255 Background: Farletuzumab (MORAb-003) is a humanized monoclonal antibody that binds to the folate receptor alpha (FRA) which is overexpressed in most epithelial ovarian cancers (EOC), butExpand
  • 5
Can elderly patients with recurrent ovarian cancer (ROC) be treated with a platinum-based doublet? Results from the CALYPSO trial.
5031 Background: In the CALYPSO trial, carboplatin (C)-pegylated liposomal doxorubicin (PLD) demonstrated a superior therapeutic index (TI) versus C-paclitaxel (P) in patients (pts) with ROC >6 moExpand
  • 4
Genome-wide association study (GWAS) of pazopanib efficacy and safety in patients with ovarian cancer who have not progressed following first-line standard therapy.
5574 Background: Pazopanib is an oral multi-kinase inhibitor of VEGFR-1, -2, -3, PDGFR-α and -β and c-Kit. In the phase III AGO-OVAR16 study (NCT00866697), pazopanib maintenance therapy significant...
Corrigendum to “Single-agent irinotecan or 5-fluorouracil and leucovorin (FOLFIRI) as second-line chemotherapy for advanced colorectal cancer; results of a randomised phase II study (DaVINCI) and
Stephen J. Clarke *, Sonia Yip , Chris Brown , Guy A. van Hazel , David T. Ransom , David Goldstein , G. Mark Jeffrey , Niall C. Tebbutt , Martin Buck , Raymond M. Lowenthal , Amy Boland , Val GebskiExpand